Profile data is unavailable for this security.
About the company
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
- Revenue in USD (TTM)174.50m
- Net income in USD-40.44m
- Incorporated2007
- Employees167.00
- LocationAkebia Therapeutics Inc245 First StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 871-2098
- Fax+1 (617) 871-2099
- Websitehttps://akebia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | 182.02m | -10.93m | 268.72m | 203.00 | -- | 0.4953 | -- | 1.48 | -0.1886 | -0.1886 | 3.15 | 9.31 | 0.2815 | 9.96 | 4.82 | 896,660.10 | -1.69 | 6.61 | -1.97 | 7.62 | 93.03 | 90.55 | -6.00 | 15.18 | 4.67 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -80.55m | 268.96m | 54.00 | -- | 2.42 | -- | -- | -1.54 | -1.54 | 0.00 | 1.97 | 0.00 | -- | -- | 0.00 | -59.70 | -40.29 | -67.82 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Chromadex Corp | 85.58m | -1.35m | 275.64m | 106.00 | -- | 8.92 | -- | 3.22 | -0.018 | -0.018 | 1.14 | 0.407 | 1.60 | 2.86 | 12.93 | 807,386.80 | -2.52 | -42.11 | -3.85 | -65.14 | 60.82 | 59.68 | -1.58 | -30.64 | 2.12 | -- | 0.0006 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 275.71m | 112.00 | -- | 0.8267 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Rezolute Inc | 0.00 | -68.46m | 281.28m | 59.00 | -- | 2.24 | -- | -- | -1.33 | -1.33 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -53.39 | -50.36 | -56.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
| AVITA Medical Inc | 54.14m | -49.83m | 282.51m | 207.00 | -- | 11.79 | -- | 5.22 | -1.95 | -1.95 | 2.12 | 0.9216 | 0.6217 | 1.46 | 7.23 | 261,541.10 | -57.22 | -- | -68.00 | -- | 86.80 | -- | -92.04 | -- | 4.81 | -13.95 | 0.6315 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -27.94m | 283.16m | 14.00 | -- | 1.81 | -- | -- | -0.4944 | -0.4944 | 0.00 | 2.46 | 0.00 | -- | -- | 0.00 | -23.00 | -- | -30.30 | -- | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 286.62m | 50.00 | -- | 2.22 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Akebia Therapeutics Inc | 174.50m | -40.44m | 288.09m | 167.00 | -- | -- | -- | 1.65 | -0.2024 | -0.2024 | 0.8803 | -0.1608 | 0.7364 | 1.36 | 7.07 | 1,044,892.00 | -17.07 | -37.42 | -29.47 | -56.00 | 82.59 | 69.13 | -23.18 | -82.25 | 0.8222 | -4.41 | 8.89 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Tscan Therapeutics Inc | 12.20m | -104.41m | 292.42m | 175.00 | -- | 1.14 | -- | 23.97 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Tectonic Therapeutic Inc | 0.00 | -58.25m | 295.87m | 13.00 | -- | 1.78 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| PepGen Inc | 0.00 | -89.14m | 299.83m | 64.00 | -- | 1.92 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 300.08m | 168.00 | -- | 0.7843 | -- | 7.40 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 302.62m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -90.69m | 303.36m | 88.00 | -- | 1.57 | -- | -- | -3.30 | -3.30 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -41.63 | -49.99 | -44.77 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0076 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Sutro Biopharma Inc | 169.36m | -124.45m | 309.00m | 304.00 | -- | 2.03 | -- | 1.82 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Data as of Sep 20 2024. Currency figures normalised to Akebia Therapeutics Inc's reporting currency: US Dollar USD
15.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.17m | 3.90% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.54m | 2.16% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 4.06m | 1.94% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 3.91m | 1.87% |
| Millennium Management LLCas of 31 Mar 2024 | 3.27m | 1.56% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.47m | 1.18% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 2.26m | 1.08% |
| Jacobs Levy Equity Management, Inc.as of 31 Mar 2024 | 1.64m | 0.78% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.41m | 0.67% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 1.41m | 0.67% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
